Opendata, web and dolomites

NANO-GROWTH

An innovative, non-invasive and de-risked system to enable the transdermal delivery of fragile therapeutic compounds for a better management of painful diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANO-GROWTH project word cloud

Explore the words cloud of the NANO-GROWTH project. It provides you a very rough idea of what is the project "NANO-GROWTH" about.

proven    nano    capsule    patients    longer    persists    skin    chronic    secure    turn    compounds    therapeutic    severe    helping    inflicting    saturated    biodegradation    dermal    lab    mature    secures    diseases    painful    receive    nerve    engineered    solution    41    altogether    relief    damage    creams    integrity    limitations    becomes    position    subsequent    efficiency    release    patches    administered    bloodstream    commercial    million    financial    neuropathy    topical    cancer    travel    unbearable    loaded    consolidate    quality    cure    astracime    gain    suffering    effect    combined    perspectives    diabetes    143    protects    adverse    life    overcomes    poor    globally    34    patch    innovative    encapsulated    leader    millions    layers    customized    pain    billion    analgesics    solutions    hire    revenues    safer    transdermal    mediated    meds    disease    reduce    people    stage    medication    encloses    barriers    healthcare    worldwide    instance    rate    scarcity    transdermally    heart    market    age   

Project "NANO-GROWTH" data sheet

The following table provides information about the project.

Coordinator
ASTRACIME SL 

Organization address
address: CALLE MONTE AUSEVA 10 BAJO
city: OVIEDO
postcode: 33012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.nanogrowth.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASTRACIME SL ES (OVIEDO) coordinator 50˙000.00

Map

 Project objective

Chronic pain affects 1.5 billion people worldwide, which means that pain affects more people than diabetes, heart disease and cancer combined. Since chronic pain persists for years, it becomes unbearable. Chronic pain is often the result from neuropathy (nerve damage), which increases with age but also due to chronic diseases. For instance, 34% of diabetes cases develop painful neuropathy, which means 143 million people affected globally. Since there is no cure, patients receive analgesics and other meds for pain relief. To avoid inflicting further pain, medication is administered transdermally using topical solutions like creams or patches. However, there are important barriers to the dermal delivery of analgesics: scarcity of viable compounds, high biodegradation rate, short effect, poor efficiency and severe adverse effects. In response, we at Astracime have developed an innovative solution that overcomes the limitations of transdermal pain relief. This NANO-GROWTH project aims to bring to market a unique dermal patch loaded with encapsulated therapeutic compounds. The customized capsule protects the integrity of the compounds as they travel through the skin layers and bloodstream. In addition, we have engineered the capsule to provide target-mediated release. Altogether, our method secures a longer and safer pain relief. After been proven at the lab scale, we now aim to take a step further towards the mature stage. Thus, in Phase 1 we aim to assess the subsequent steps needed to secure this project from all technical, commercial and financial perspectives. This project encloses significant growth potential for Astracime, allowing us to consolidate a leader position in the field of pain management. Indeed, we expect to gain €41 million in revenues and hire 30 new people in 5 years. In turn, this project will contribute to improve the quality of life of millions of patients suffering from pain, while helping to reduce costs to our saturated healthcare system.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANO-GROWTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANO-GROWTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More